New weight loss drugs in 2026,
verified record by record.
Track 13 active and recently reported programs in one dated, source-led view. Compare trial stage, route, regulatory milestones, and what the evidence cannot answer yet.
Which new weight loss drugs are in the 2026 pipeline?
This tracker covers 13 programs. Mazdutide and Ecnoglutide have China-specific approvals, CagriSema is under FDA review, and the other listed programs remain investigational. A Phase 3 result or regulatory application is not an approval.
Registry data checked July 24, 2026 at 9:00 AM UTCNo affiliate links or research-vial prices
Profiles tracked13One evidence ledger per molecule or fixed-dose combination
Approval boundary02Two programs have indication-specific medicine approvals in China
Commercial links00Pipeline profiles contain no affiliate or research-vial links
Official trial records26861 recruiting records across 53 countries
Evidence watchlist
Six records worth watching now.
These are not rankings or recommendations. They are the records with a clear current milestone, distinct mechanism, or evidence question that needs careful verification. Each card opens the source ledger and unresolved questions.
01Novo Nordisk
CagriSema
cagrilintide + semaglutide
- Components
- 2 peptides
- Current record
- Phase 3 / US regulatory review
02Innovent Biologics; licensed from Eli Lilly for China
Mazdutide
IBI362
- China approval
- June + September 2025
- Current record
- China approvals active; Phase 3 and indication-expansion studies continue
03Eli Lilly and Company
Eloralintide
LY3841136
- Molecular identity
- Single peptide
- Current record
- Phase 3 ENLIGHTEN program recruiting
04Eli Lilly and Company
Retatrutide
LY3437943
- Drug class
- Triple agonist
- Current record
- Phase 3 program reporting results
05Novo Nordisk
Zenagamtide
amycretin
- Current name
- Zenagamtide
- Current record
- Phase 3 development underway
06Amgen
MariTide
maridebart cafraglutide
- Lead schedule
- Monthly
- Current record
- Phase 3 program active
Program finder
Compare status, route, and development stage.
Search names, aliases, sponsors, routes, or mechanisms. Every matching card remains tied to one sourced profile, and the status filters do not turn a trial milestone into product approval.
Status
Route
Active Phase 3
MariTide
maridebart cafraglutide · AMG 133AmgenCurrent recordPhase 3 program activeInvestigational - not FDA approved
Route and mechanismSubcutaneous injectionGLP-1 receptor agonist + GIP receptor antagonist
CheckedJuly 20, 2026↗
Active Phase 3
Zenagamtide
amycretin · NNC0487-0111 · AMAZE 7Novo NordiskCurrent recordPhase 3 development underwayInvestigational - not FDA approved
Route and mechanismOnce-daily oral or once-weekly subcutaneousGLP-1 + amylin receptor agonist
CheckedJuly 20, 2026↗
US FDA review
CagriSema
cagrilintide + semaglutide · REDEFINE 1 · REIMAGINE 1-3Novo NordiskCurrent recordPhase 3 / US regulatory reviewSubmitted to FDA - not yet approved
Route and mechanismOnce-weekly subcutaneous injectionAmylin analogue + GLP-1 receptor agonist
CheckedJuly 20, 2026↗
Active Phase 3
Cagrilintide
AM833 · NNC0174-0833Novo NordiskCurrent recordPhase 3 monotherapy programInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionLong-acting amylin analogue
CheckedJuly 20, 2026↗
Active Phase 3
Retatrutide
LY3437943 · triple agonist · reta · reta peptideEli Lilly and CompanyCurrent recordPhase 3 program reporting resultsInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionGIP + GLP-1 + glucagon receptor agonist
CheckedJuly 20, 2026↗
China approvals
Mazdutide
IBI362 · LY3305677 · GLP-1/glucagon dual agonistInnovent Biologics; licensed from Eli Lilly for ChinaCurrent recordChina approvals active; Phase 3 and indication-expansion studies continueApproved in China for chronic weight management and type 2 diabetes; not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionGLP-1 and glucagon receptor dual agonist
CheckedJuly 22, 2026↗
Active Phase 3
Enicepatide
CT-388 · RO7795068 · RG6640Roche / Carmot TherapeuticsCurrent recordPhase 3 ENITH program recruitingInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionSignal-biased GLP-1 + GIP receptor dual agonist
CheckedJuly 18, 2026↗
Active Phase 3
Eloralintide
LY3841136 · eloralintide peptide · selective amylin receptor agonistEli Lilly and CompanyCurrent recordPhase 3 ENLIGHTEN program recruitingInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionSelective amylin 1 receptor agonist
CheckedJuly 22, 2026↗
Earlier or planned
Petrelintide
ZP8396 · long-acting amylin analogueZealand Pharma + RocheCurrent recordPhase 3 planned; Phase 2 program activeInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionLong-acting amylin analogue
CheckedJuly 17, 2026↗
Active Phase 3
Survodutide
BI 456906 · glucagon/GLP-1 dual agonistBoehringer Ingelheim + Zealand PharmaCurrent recordPhase 3 program active and reportingInvestigational - not approved for marketing
Route and mechanismOnce-weekly subcutaneous injectionGlucagon + GLP-1 receptor dual agonist
CheckedJuly 20, 2026↗
Active Phase 3
VK2735
Viking VK2735 · oral VK2735 · GLP-1/GIP dual agonistViking TherapeuticsCurrent recordSubcutaneous Phase 3 active; oral Phase 3 plannedInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injection and once-daily oral tabletGIP and GLP-1 receptor dual agonist
CheckedJuly 18, 2026↗
China approvals
Ecnoglutide
XW003 · Sciwind ecnoglutide · cAMP-biased GLP-1 receptor agonist · 埃诺格鲁肽Sciwind Biosciences; Pfizer commercialization partner in Mainland ChinaCurrent recordChina approvals active; indication-expansion studies continueApproved in China for type 2 diabetes and chronic weight management; not FDA approved
Route and mechanismOnce-weekly subcutaneous injectioncAMP-signalling-biased GLP-1 receptor agonist
CheckedJuly 18, 2026↗
Earlier or planned
Pemvidutide
ALT-801 · balanced GLP-1/glucagon dual agonist · Altimmune pemvidutideAltimmuneCurrent recordPhase 2 programs active; MASH Phase 3 plannedInvestigational - not FDA approved
Route and mechanismOnce-weekly subcutaneous injectionBalanced 1:1 GLP-1 and glucagon receptor dual agonist
CheckedJuly 18, 2026↗
Use the evidence
Go from a headline to the underlying record.
Featured comparisons
Six useful comparisons, without fake winners.
Start with the pairs most useful for current pipeline questions. The full library contains 29 evidence comparisons, without fake winners.
01Eloralintide vs Retatrutide6 fields · checked July 20, 2026↗02Mazdutide vs Retatrutide5 fields · checked July 22, 2026↗03CagriSema vs Retatrutide4 fields · checked July 20, 2026↗04Zenagamtide vs CagriSema5 fields · checked July 20, 2026↗05MariTide vs CagriSema5 fields · checked July 20, 2026↗06CagriSema vs Survodutide5 fields · checked July 20, 2026↗
Open all 29 clinical and regulatory comparisons How we publish
No superlatives without a head-to-head trial.
“Strongest,” “fastest,” and “most convenient” are not evidence categories. We attach every percentage to its population, duration, comparator, estimand, and source.
A sponsor filing is a real milestone, but it is not an approval. A studied quarterly schedule is not automatically an approved quarterly dose. A small Phase 1 signal is not a market ranking.
Search the official clinical trial registry snapshot →Open the weight-loss trial results and study design tool →Read the editorial method →